Contributions
Abstract: PB2036
Type: Publication Only
Background
Incidence of multiple myeloma (MM) is increasing in Asian countries, and prevalence is also expected to rise due to ageing populations and therapeutic advances. Most patients receive care outside the clinical trial setting, therefore the generation of real-world evidence (RWE) on practice, including long-term monitoring and evaluation of treatment strategies, is important to inform optimal treatment for MM and improve outcomes. Some country-specific data are available in Asia, but few at a regional level.
Aims
The Asia-Pacific (APAC) Myeloma and Related Diseases Registry (MRDR) was established in 2018 to collect a standardised APAC dataset for analysis and benchmarking. Clinical experts and opinion leaders from the participating countries provide local clinical context and registry oversight. Participating hospitals are responsible for obtaining local ethics approval, patient recruitment, and data collection.
Methods
The APAC MRDR prospectively collects observational data on patient characteristics, diagnosis, medical history, treatment (including supportive therapies), and outcomes (overall and progression-free survival, and quality of life using the EQ-5D-5L) on newly diagnosed MM (NDMM), plasma cell leukaemia, plasmacytoma, and MGUS patients via a secure, country-specific, web-based database. Participants are reviewed 4-monthly for a minimum of 2 years. Preliminary data from October 2018 to January 2020 were analysed.
Results
Nineteen hospitals have ethics approval to participate and patient recruitment has commenced at 10 hospitals in Korea, Singapore, and more recently, Malaysia. Sites in Taiwan will also start recruitment in 2020. To date, a total of 335 patients (202 NDMM) have been enrolled, of which, data from 173 (86%) NDMM participants from Korea and Singapore were available for analysis. Results are presented in Table 1.
Table 1. Characteristics of NDMM participants by country and total cohort
Characteristics: median [IQR] or fraction (%) | Korea | Singapore | Total |
N | 130 | 43 | 173 |
Age at diagnosis | 64 [57,72] | 65 [59,70] | 64 [58,70] |
Age at diagnosis, ≥70 years | 36/130 (28%) | 12/43 (28%) | 48/173 (28%) |
Gender (male) | 68/130 (52%) | 21/43 (49%) | 89/173 (51%) |
EQ5D VAS Health State Score* | 70 [50,80] | 78 [60,90] | 70 [50,80] |
Comorbidity present | 54/130 (42%) | 26/43 (60%) | 80/173 (46%) |
First-line chemotherapy |
|
|
|
Time to treatment (days) from diagnosis | 8 [3,17], N=123 | 8 [3,16], N=39 | 8 [3,16], N=162 |
Overall Response Rate (≥PR) | 92/99 (93%) | 18/21 (86%) | 110/120 (92%) |
Most frequently used regimens^ | 1. VTd: 55/123 (45%) | 1. VTd: 17/39 (44%) | 1. VTd: 72/162 (44%) |
2. MPV: 33/123 (27%) | 2. VCd: 10/39 (26%) | 2. MPV: 34/162 (21%) |
*Self-reported: 100=best health imaginable, 0=the worst. ^Chemotherapy codes: VTd (bortezomib/ thalidomide/ dexamethasone); MPV (melphalan/ prednisone/ bortezomib), VCd (bortezomib/ cyclophosphamide/ dexamethasone).
Conclusion
The APAC MRDR database is maturing and will provide RWE that will contribute to our understanding on current myeloma treatment strategies and patient outcomes in the APAC region. The registry can also serve as a regional resource by providing infrastructure and identifying eligible participants for clinical trials and other research.
Session topic: 14. Myeloma and other monoclonal gammopathies - Clinical
Keyword(s): Chemotherapy, Clinical data, Epidemiology, Multiple myeloma
Abstract: PB2036
Type: Publication Only
Background
Incidence of multiple myeloma (MM) is increasing in Asian countries, and prevalence is also expected to rise due to ageing populations and therapeutic advances. Most patients receive care outside the clinical trial setting, therefore the generation of real-world evidence (RWE) on practice, including long-term monitoring and evaluation of treatment strategies, is important to inform optimal treatment for MM and improve outcomes. Some country-specific data are available in Asia, but few at a regional level.
Aims
The Asia-Pacific (APAC) Myeloma and Related Diseases Registry (MRDR) was established in 2018 to collect a standardised APAC dataset for analysis and benchmarking. Clinical experts and opinion leaders from the participating countries provide local clinical context and registry oversight. Participating hospitals are responsible for obtaining local ethics approval, patient recruitment, and data collection.
Methods
The APAC MRDR prospectively collects observational data on patient characteristics, diagnosis, medical history, treatment (including supportive therapies), and outcomes (overall and progression-free survival, and quality of life using the EQ-5D-5L) on newly diagnosed MM (NDMM), plasma cell leukaemia, plasmacytoma, and MGUS patients via a secure, country-specific, web-based database. Participants are reviewed 4-monthly for a minimum of 2 years. Preliminary data from October 2018 to January 2020 were analysed.
Results
Nineteen hospitals have ethics approval to participate and patient recruitment has commenced at 10 hospitals in Korea, Singapore, and more recently, Malaysia. Sites in Taiwan will also start recruitment in 2020. To date, a total of 335 patients (202 NDMM) have been enrolled, of which, data from 173 (86%) NDMM participants from Korea and Singapore were available for analysis. Results are presented in Table 1.
Table 1. Characteristics of NDMM participants by country and total cohort
Characteristics: median [IQR] or fraction (%) | Korea | Singapore | Total |
N | 130 | 43 | 173 |
Age at diagnosis | 64 [57,72] | 65 [59,70] | 64 [58,70] |
Age at diagnosis, ≥70 years | 36/130 (28%) | 12/43 (28%) | 48/173 (28%) |
Gender (male) | 68/130 (52%) | 21/43 (49%) | 89/173 (51%) |
EQ5D VAS Health State Score* | 70 [50,80] | 78 [60,90] | 70 [50,80] |
Comorbidity present | 54/130 (42%) | 26/43 (60%) | 80/173 (46%) |
First-line chemotherapy |
|
|
|
Time to treatment (days) from diagnosis | 8 [3,17], N=123 | 8 [3,16], N=39 | 8 [3,16], N=162 |
Overall Response Rate (≥PR) | 92/99 (93%) | 18/21 (86%) | 110/120 (92%) |
Most frequently used regimens^ | 1. VTd: 55/123 (45%) | 1. VTd: 17/39 (44%) | 1. VTd: 72/162 (44%) |
2. MPV: 33/123 (27%) | 2. VCd: 10/39 (26%) | 2. MPV: 34/162 (21%) |
*Self-reported: 100=best health imaginable, 0=the worst. ^Chemotherapy codes: VTd (bortezomib/ thalidomide/ dexamethasone); MPV (melphalan/ prednisone/ bortezomib), VCd (bortezomib/ cyclophosphamide/ dexamethasone).
Conclusion
The APAC MRDR database is maturing and will provide RWE that will contribute to our understanding on current myeloma treatment strategies and patient outcomes in the APAC region. The registry can also serve as a regional resource by providing infrastructure and identifying eligible participants for clinical trials and other research.
Session topic: 14. Myeloma and other monoclonal gammopathies - Clinical
Keyword(s): Chemotherapy, Clinical data, Epidemiology, Multiple myeloma